Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTaP Vaccine Production Is Sufficient For Return To 5-Dose Schedule - CDC

Executive Summary

The National Immunization Program estimates that there is sufficient DTaP vaccine in the pipeline to return to the routine five-dose schedule.

You may also be interested in...



Aventis To Boost Tetanus Vaccine Production To Meet Needs By Year-End

Aventis-Pasteur has begun scaling up tetanus vaccine component production and expects to meet U.S. tetanus needs by the end of the year.

Wyeth-Ayerst Acel-Imune Discontinued; DTaP Vaccine Had Sales Of $71 Mil.

Wyeth-Ayerst is discontinuing the DTaP vaccine Acel-Imune, the company said.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS038140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel